Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Ear­li­er on Mon­day, new Sanofi CEO Paul Hud­son bait­ed the hook on his up­com­ing strat­e­gy pre­sen­ta­tion Tues­day with a tell-tale deal to buy Syn­thorx for $2.5 bil­lion. That fits square­ly with hints that he’s point­ing the com­pa­ny to a big­ger fu­ture in on­col­o­gy, which al­so squares with a ma­jor in­dus­try tilt.

In a big re­veal lat­er in the day, though, Hud­son of­fered a slate of stun­ners on his plans to sur­gi­cal­ly dis­sect and re­assem­ble the port­foloio, say­ing that the com­pa­ny is drop­ping car­dio and di­a­betes re­search — which cov­ers two of its biggest fran­chise are­nas. Sanofi missed the boat on de­vel­op­ing new di­a­betes drugs, and now it’s pulling out en­tire­ly. As part of the pull­back, it’s drop­ping ef­pe­gle­natide, their once-week­ly GLP-1 in­jec­tion for di­a­betes.

“To be out of car­dio­vas­cu­lar and di­a­betes is not easy for a com­pa­ny like ours with an in­cred­i­bly proud his­to­ry,” Hud­son said on a call with re­porters, ac­cord­ing to the Wall Street Jour­nal. “As tough a choice as that is, we’re mak­ing that choice.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER